Concepts (349)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Exercise | 25 | 2023 | 939 | 1.990 |
Why?
|
| Diabetes Mellitus, Type 2 | 14 | 2022 | 692 | 1.820 |
Why?
|
| Transgender Persons | 3 | 2018 | 69 | 1.420 |
Why?
|
| Blood Glucose | 18 | 2018 | 483 | 1.170 |
Why?
|
| Walking | 7 | 2023 | 238 | 0.860 |
Why?
|
| Insulin | 16 | 2018 | 686 | 0.820 |
Why?
|
| Muscle, Skeletal | 11 | 2025 | 738 | 0.810 |
Why?
|
| Exercise Test | 13 | 2023 | 252 | 0.770 |
Why?
|
| Periodicals as Topic | 1 | 2024 | 175 | 0.720 |
Why?
|
| Hypothyroidism | 1 | 2021 | 43 | 0.700 |
Why?
|
| Postprandial Period | 2 | 2018 | 19 | 0.640 |
Why?
|
| Transsexualism | 2 | 2013 | 14 | 0.610 |
Why?
|
| Mentors | 1 | 2020 | 119 | 0.610 |
Why?
|
| Male | 56 | 2025 | 29814 | 0.580 |
Why?
|
| Monitoring, Ambulatory | 2 | 2009 | 57 | 0.570 |
Why?
|
| Hormone Replacement Therapy | 1 | 2017 | 29 | 0.540 |
Why?
|
| Obesity | 9 | 2018 | 1230 | 0.510 |
Why?
|
| Humans | 66 | 2025 | 63292 | 0.510 |
Why?
|
| Gait | 4 | 2023 | 119 | 0.500 |
Why?
|
| Hypoglycemic Agents | 6 | 2013 | 217 | 0.500 |
Why?
|
| Community Health Workers | 1 | 2016 | 37 | 0.500 |
Why?
|
| Professional Competence | 1 | 2016 | 93 | 0.480 |
Why?
|
| Female | 50 | 2025 | 32787 | 0.480 |
Why?
|
| Needs Assessment | 1 | 2016 | 198 | 0.470 |
Why?
|
| Energy Metabolism | 8 | 2010 | 379 | 0.420 |
Why?
|
| Glycogen | 4 | 2007 | 42 | 0.400 |
Why?
|
| Metformin | 5 | 2013 | 73 | 0.390 |
Why?
|
| Weight Loss | 2 | 2013 | 272 | 0.390 |
Why?
|
| Adult | 34 | 2023 | 16782 | 0.380 |
Why?
|
| Self Care | 3 | 2008 | 212 | 0.380 |
Why?
|
| Glucose | 7 | 2008 | 467 | 0.380 |
Why?
|
| Diabetes Mellitus | 4 | 2011 | 537 | 0.370 |
Why?
|
| Cultural Characteristics | 2 | 2003 | 37 | 0.350 |
Why?
|
| Middle Aged | 27 | 2023 | 17549 | 0.320 |
Why?
|
| Urban Population | 4 | 2003 | 193 | 0.320 |
Why?
|
| Nitric Oxide Synthase | 1 | 2009 | 47 | 0.320 |
Why?
|
| Dexamethasone | 3 | 2007 | 205 | 0.310 |
Why?
|
| Saphenous Vein | 1 | 2009 | 52 | 0.310 |
Why?
|
| Myocardial Revascularization | 1 | 2009 | 76 | 0.310 |
Why?
|
| Metabolic Equivalent | 4 | 2023 | 13 | 0.300 |
Why?
|
| Attitude to Health | 4 | 2000 | 289 | 0.300 |
Why?
|
| Insulin Resistance | 7 | 2011 | 410 | 0.300 |
Why?
|
| Gastric Bypass | 1 | 2009 | 76 | 0.290 |
Why?
|
| Muscle Contraction | 3 | 2015 | 202 | 0.280 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2016 | 216 | 0.280 |
Why?
|
| Obesity, Morbid | 1 | 2009 | 98 | 0.280 |
Why?
|
| Glycogen Synthase | 1 | 2007 | 4 | 0.270 |
Why?
|
| Cardiovascular Diseases | 2 | 2013 | 834 | 0.270 |
Why?
|
| Gene Expression Regulation | 3 | 2011 | 1617 | 0.250 |
Why?
|
| Androgens | 1 | 2005 | 48 | 0.240 |
Why?
|
| Aged | 17 | 2025 | 14390 | 0.230 |
Why?
|
| Acidosis | 1 | 2025 | 27 | 0.230 |
Why?
|
| Oxygen Consumption | 5 | 2010 | 209 | 0.230 |
Why?
|
| Testosterone | 1 | 2005 | 121 | 0.230 |
Why?
|
| Muscle Fatigue | 1 | 2025 | 48 | 0.220 |
Why?
|
| Correspondence as Topic | 1 | 2024 | 10 | 0.220 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2023 | 3 | 0.210 |
Why?
|
| Editorial Policies | 1 | 2024 | 55 | 0.210 |
Why?
|
| Acceleration | 1 | 2023 | 35 | 0.200 |
Why?
|
| Heptanoic Acids | 2 | 2013 | 22 | 0.200 |
Why?
|
| Pyrroles | 2 | 2013 | 51 | 0.200 |
Why?
|
| Young Adult | 12 | 2023 | 4683 | 0.190 |
Why?
|
| Running | 1 | 2023 | 84 | 0.190 |
Why?
|
| Diet, Diabetic | 2 | 2000 | 13 | 0.190 |
Why?
|
| Myocarditis | 1 | 2023 | 66 | 0.190 |
Why?
|
| Gastric Inhibitory Polypeptide | 1 | 2022 | 3 | 0.190 |
Why?
|
| Overweight | 2 | 2018 | 250 | 0.190 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2022 | 13 | 0.190 |
Why?
|
| Actins | 1 | 2023 | 259 | 0.190 |
Why?
|
| Aging | 2 | 2025 | 746 | 0.180 |
Why?
|
| Cross-Sectional Studies | 6 | 2022 | 2571 | 0.180 |
Why?
|
| Physical Exertion | 2 | 2019 | 80 | 0.180 |
Why?
|
| Hyperglycemia | 2 | 2018 | 104 | 0.170 |
Why?
|
| NF-kappa B | 2 | 2013 | 469 | 0.170 |
Why?
|
| Monosaccharide Transport Proteins | 2 | 1998 | 43 | 0.160 |
Why?
|
| Thyroid Diseases | 1 | 2020 | 26 | 0.160 |
Why?
|
| Carbohydrate Metabolism | 5 | 2010 | 49 | 0.160 |
Why?
|
| Coronary Artery Bypass | 3 | 2011 | 297 | 0.160 |
Why?
|
| Motor Activity | 2 | 2016 | 346 | 0.160 |
Why?
|
| Pilot Projects | 2 | 2023 | 1006 | 0.160 |
Why?
|
| Metabolic Syndrome | 2 | 2013 | 142 | 0.160 |
Why?
|
| Universities | 1 | 2000 | 158 | 0.150 |
Why?
|
| Muscle Strength | 3 | 2013 | 40 | 0.150 |
Why?
|
| Energy Intake | 3 | 2008 | 171 | 0.150 |
Why?
|
| Patient Education as Topic | 3 | 2009 | 474 | 0.150 |
Why?
|
| History, 21st Century | 1 | 2020 | 171 | 0.150 |
Why?
|
| Models, Biological | 3 | 2010 | 1177 | 0.150 |
Why?
|
| United States | 2 | 2024 | 7826 | 0.150 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2009 | 62 | 0.150 |
Why?
|
| History, 20th Century | 1 | 2020 | 231 | 0.150 |
Why?
|
| Hexoses | 1 | 1998 | 2 | 0.150 |
Why?
|
| Blood Pressure | 2 | 2018 | 509 | 0.150 |
Why?
|
| Motor Skills | 1 | 2018 | 61 | 0.150 |
Why?
|
| Students | 1 | 2000 | 217 | 0.140 |
Why?
|
| Microcirculation | 1 | 1998 | 52 | 0.140 |
Why?
|
| Dietary Carbohydrates | 2 | 2008 | 61 | 0.140 |
Why?
|
| Massachusetts | 4 | 2016 | 2075 | 0.140 |
Why?
|
| Empathy | 1 | 2018 | 67 | 0.140 |
Why?
|
| Diabetes Complications | 3 | 2011 | 106 | 0.140 |
Why?
|
| Emotional Intelligence | 1 | 2017 | 4 | 0.140 |
Why?
|
| Reading | 1 | 2018 | 92 | 0.140 |
Why?
|
| Fatty Acids | 1 | 2018 | 200 | 0.140 |
Why?
|
| Comprehension | 1 | 2018 | 138 | 0.140 |
Why?
|
| Vitamin D | 1 | 2018 | 140 | 0.130 |
Why?
|
| Cerebrovascular Circulation | 1 | 1998 | 180 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2020 | 268 | 0.130 |
Why?
|
| Double-Blind Method | 6 | 2016 | 738 | 0.130 |
Why?
|
| Feasibility Studies | 2 | 2009 | 568 | 0.130 |
Why?
|
| Creatine Kinase | 2 | 2013 | 42 | 0.130 |
Why?
|
| Sucrose | 1 | 1996 | 29 | 0.130 |
Why?
|
| Professional-Patient Relations | 1 | 2017 | 128 | 0.130 |
Why?
|
| Self-Assessment | 1 | 2016 | 60 | 0.130 |
Why?
|
| Biomarkers | 4 | 2011 | 1396 | 0.120 |
Why?
|
| Muscle Proteins | 1 | 1996 | 117 | 0.120 |
Why?
|
| Anticholesteremic Agents | 1 | 2016 | 35 | 0.120 |
Why?
|
| Counseling | 2 | 2009 | 362 | 0.120 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2007 | 619 | 0.120 |
Why?
|
| Health Status | 1 | 1998 | 435 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2000 | 621 | 0.120 |
Why?
|
| Pain | 2 | 2009 | 406 | 0.120 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1994 | 22 | 0.110 |
Why?
|
| Rats | 4 | 2007 | 1977 | 0.110 |
Why?
|
| Health Behavior | 1 | 1998 | 466 | 0.110 |
Why?
|
| Cross-Over Studies | 5 | 2018 | 161 | 0.110 |
Why?
|
| Extracellular Matrix | 1 | 2015 | 139 | 0.110 |
Why?
|
| Heart Rate | 4 | 2013 | 321 | 0.110 |
Why?
|
| Adaptation, Physiological | 1 | 2015 | 129 | 0.110 |
Why?
|
| Fatty Acids, Nonesterified | 3 | 2009 | 56 | 0.100 |
Why?
|
| Analysis of Variance | 3 | 2010 | 608 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 357 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2009 | 735 | 0.100 |
Why?
|
| C-Reactive Protein | 2 | 2013 | 166 | 0.100 |
Why?
|
| Cardioplegic Solutions | 2 | 2004 | 9 | 0.100 |
Why?
|
| Musculoskeletal Pain | 1 | 2012 | 28 | 0.100 |
Why?
|
| Estrogens | 2 | 2023 | 116 | 0.100 |
Why?
|
| Glucose Intolerance | 1 | 2013 | 90 | 0.090 |
Why?
|
| Linear Models | 2 | 2010 | 409 | 0.090 |
Why?
|
| ROC Curve | 2 | 2023 | 281 | 0.090 |
Why?
|
| Aged, 80 and over | 5 | 2022 | 5448 | 0.090 |
Why?
|
| Primary Health Care | 1 | 2017 | 690 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2017 | 2071 | 0.090 |
Why?
|
| Pericytes | 1 | 2011 | 15 | 0.090 |
Why?
|
| Body Weight | 2 | 2007 | 377 | 0.090 |
Why?
|
| Rest | 3 | 2019 | 46 | 0.090 |
Why?
|
| Graves Disease | 1 | 2011 | 16 | 0.090 |
Why?
|
| Prediabetic State | 1 | 2011 | 53 | 0.090 |
Why?
|
| Diabetic Angiopathies | 2 | 1990 | 24 | 0.090 |
Why?
|
| Thyroid Gland | 2 | 2007 | 81 | 0.080 |
Why?
|
| Parathyroid Hormone | 1 | 2010 | 43 | 0.080 |
Why?
|
| Radiation Dosage | 1 | 2011 | 132 | 0.080 |
Why?
|
| Bicycling | 1 | 2010 | 21 | 0.080 |
Why?
|
| Brain | 1 | 1998 | 1555 | 0.080 |
Why?
|
| Coronary Disease | 2 | 1990 | 246 | 0.080 |
Why?
|
| Cholesterol, LDL | 1 | 2009 | 103 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 214 | 0.080 |
Why?
|
| Pulmonary Gas Exchange | 2 | 2008 | 43 | 0.080 |
Why?
|
| Statistics as Topic | 1 | 2009 | 147 | 0.080 |
Why?
|
| Appetite Regulation | 1 | 2008 | 8 | 0.080 |
Why?
|
| Monitoring, Intraoperative | 1 | 2009 | 46 | 0.080 |
Why?
|
| Meta-Analysis as Topic | 1 | 2009 | 77 | 0.070 |
Why?
|
| West Indies | 2 | 1998 | 6 | 0.070 |
Why?
|
| Hormones | 1 | 2008 | 60 | 0.070 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 175 | 0.070 |
Why?
|
| Eating | 1 | 2009 | 138 | 0.070 |
Why?
|
| Psychotropic Drugs | 1 | 2008 | 81 | 0.070 |
Why?
|
| Educational Status | 1 | 2009 | 275 | 0.070 |
Why?
|
| Diet | 3 | 2008 | 524 | 0.070 |
Why?
|
| Hyperinsulinism | 2 | 1998 | 26 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2009 | 863 | 0.070 |
Why?
|
| Perception | 1 | 2008 | 174 | 0.070 |
Why?
|
| Treatment Outcome | 7 | 2013 | 5651 | 0.070 |
Why?
|
| Calcium | 1 | 2010 | 573 | 0.060 |
Why?
|
| Glucose Clamp Technique | 3 | 2011 | 57 | 0.060 |
Why?
|
| Potassium | 2 | 2004 | 101 | 0.060 |
Why?
|
| Time Factors | 6 | 2011 | 3759 | 0.060 |
Why?
|
| Hormone Antagonists | 1 | 2005 | 12 | 0.060 |
Why?
|
| Lipid Peroxidation | 1 | 2005 | 65 | 0.060 |
Why?
|
| Deoxyadenine Nucleotides | 1 | 2025 | 3 | 0.060 |
Why?
|
| Calorimetry, Indirect | 2 | 2019 | 31 | 0.060 |
Why?
|
| Qualitative Research | 1 | 2009 | 683 | 0.060 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2005 | 87 | 0.060 |
Why?
|
| Viscosity | 1 | 2025 | 51 | 0.060 |
Why?
|
| Elasticity | 1 | 2025 | 43 | 0.060 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2009 | 266 | 0.060 |
Why?
|
| Myosin Heavy Chains | 1 | 2025 | 44 | 0.060 |
Why?
|
| Drug Costs | 1 | 2005 | 56 | 0.060 |
Why?
|
| Life Style | 2 | 2011 | 311 | 0.060 |
Why?
|
| Animals | 5 | 2023 | 20631 | 0.060 |
Why?
|
| Phosphates | 1 | 2025 | 93 | 0.060 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2025 | 93 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2005 | 369 | 0.050 |
Why?
|
| Interviews as Topic | 2 | 1998 | 509 | 0.050 |
Why?
|
| Flutamide | 1 | 2023 | 4 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 463 | 0.050 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2023 | 11 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2003 | 2674 | 0.050 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2003 | 2 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2005 | 462 | 0.050 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2003 | 32 | 0.050 |
Why?
|
| Nutrition Policy | 1 | 2003 | 39 | 0.050 |
Why?
|
| Lipid Metabolism | 3 | 2010 | 220 | 0.050 |
Why?
|
| Inflammation | 1 | 2009 | 1146 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2005 | 360 | 0.050 |
Why?
|
| Walking Speed | 1 | 2022 | 23 | 0.050 |
Why?
|
| Adolescent | 4 | 2010 | 6238 | 0.050 |
Why?
|
| Protease Inhibitors | 1 | 2003 | 102 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2010 | 608 | 0.050 |
Why?
|
| Oxidation-Reduction | 3 | 2010 | 325 | 0.050 |
Why?
|
| Body Composition | 3 | 2008 | 152 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 453 | 0.050 |
Why?
|
| Progesterone | 1 | 2002 | 163 | 0.050 |
Why?
|
| Longevity | 1 | 2022 | 113 | 0.050 |
Why?
|
| Depression | 1 | 2008 | 891 | 0.040 |
Why?
|
| Nutrition Disorders | 1 | 2001 | 7 | 0.040 |
Why?
|
| Homebound Persons | 1 | 2001 | 7 | 0.040 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2000 | 13 | 0.040 |
Why?
|
| Placebos | 2 | 2012 | 72 | 0.040 |
Why?
|
| Poverty | 1 | 2003 | 296 | 0.040 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2011 | 85 | 0.040 |
Why?
|
| Algorithms | 3 | 2011 | 1001 | 0.040 |
Why?
|
| Peer Group | 1 | 2000 | 105 | 0.040 |
Why?
|
| Thyroid Hormones | 3 | 2008 | 78 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 433 | 0.040 |
Why?
|
| Heuristics | 1 | 2019 | 8 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2010 | 147 | 0.040 |
Why?
|
| Meals | 1 | 2018 | 20 | 0.040 |
Why?
|
| Islets of Langerhans | 1 | 2000 | 279 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2011 | 581 | 0.040 |
Why?
|
| Nutritional Sciences | 1 | 1998 | 32 | 0.040 |
Why?
|
| Streptozocin | 1 | 1998 | 22 | 0.040 |
Why?
|
| Dietary Sucrose | 1 | 1998 | 24 | 0.040 |
Why?
|
| Glucose Transporter Type 1 | 1 | 1998 | 51 | 0.040 |
Why?
|
| Body Image | 1 | 1998 | 31 | 0.040 |
Why?
|
| Risk Factors | 3 | 2013 | 5338 | 0.040 |
Why?
|
| HIV-1 | 1 | 2003 | 721 | 0.030 |
Why?
|
| Reference Values | 1 | 1998 | 335 | 0.030 |
Why?
|
| Kinetics | 2 | 2011 | 760 | 0.030 |
Why?
|
| Medical Records | 1 | 1998 | 137 | 0.030 |
Why?
|
| Boston | 1 | 1998 | 252 | 0.030 |
Why?
|
| Postoperative Complications | 2 | 2004 | 1303 | 0.030 |
Why?
|
| Age Factors | 1 | 2021 | 1560 | 0.030 |
Why?
|
| Glucose Transporter Type 4 | 1 | 1996 | 60 | 0.030 |
Why?
|
| Health Surveys | 1 | 1998 | 313 | 0.030 |
Why?
|
| Lactic Acid | 2 | 2010 | 76 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 1996 | 293 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 1998 | 259 | 0.030 |
Why?
|
| Accelerometry | 1 | 2016 | 63 | 0.030 |
Why?
|
| Tenascin | 1 | 2015 | 4 | 0.030 |
Why?
|
| Satellite Cells, Skeletal Muscle | 1 | 2015 | 15 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2000 | 760 | 0.030 |
Why?
|
| Laminin | 1 | 2015 | 78 | 0.030 |
Why?
|
| Caribbean Region | 1 | 1994 | 21 | 0.030 |
Why?
|
| Myocardium | 1 | 1996 | 274 | 0.030 |
Why?
|
| Collagen | 1 | 2015 | 123 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 172 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2011 | 3285 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 1996 | 295 | 0.030 |
Why?
|
| Myalgia | 1 | 2013 | 2 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2015 | 1539 | 0.030 |
Why?
|
| Hypertension | 1 | 2018 | 584 | 0.030 |
Why?
|
| Resistance Training | 1 | 2013 | 22 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2013 | 73 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2012 | 79 | 0.020 |
Why?
|
| Muscles | 1 | 2013 | 179 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 319 | 0.020 |
Why?
|
| Adiposity | 1 | 2013 | 83 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 839 | 0.020 |
Why?
|
| PAX7 Transcription Factor | 1 | 2011 | 9 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2011 | 32 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2011 | 46 | 0.020 |
Why?
|
| Triglycerides | 1 | 2013 | 244 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2011 | 174 | 0.020 |
Why?
|
| Iodine Radioisotopes | 1 | 2011 | 52 | 0.020 |
Why?
|
| Nonlinear Dynamics | 1 | 2011 | 25 | 0.020 |
Why?
|
| Radiometry | 1 | 2011 | 36 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2011 | 84 | 0.020 |
Why?
|
| Hypoglycemia | 1 | 2011 | 65 | 0.020 |
Why?
|
| Antigens | 1 | 2011 | 147 | 0.020 |
Why?
|
| Coronary Artery Disease | 2 | 2011 | 310 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 542 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 10827 | 0.020 |
Why?
|
| Ghrelin | 1 | 2008 | 18 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1602 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2011 | 2460 | 0.020 |
Why?
|
| DNA | 1 | 2013 | 832 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2010 | 309 | 0.020 |
Why?
|
| Leptin | 1 | 2008 | 85 | 0.020 |
Why?
|
| Electron Transport Complex I | 1 | 2008 | 15 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2009 | 85 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2008 | 121 | 0.020 |
Why?
|
| Anaerobic Threshold | 1 | 2007 | 12 | 0.020 |
Why?
|
| Iodine | 1 | 1988 | 19 | 0.020 |
Why?
|
| Glycerol | 1 | 2007 | 32 | 0.020 |
Why?
|
| Thoracic Surgery | 1 | 2009 | 71 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2007 | 76 | 0.020 |
Why?
|
| Feedback | 1 | 2007 | 93 | 0.020 |
Why?
|
| Homeostasis | 1 | 2010 | 370 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2010 | 937 | 0.020 |
Why?
|
| Weight Gain | 1 | 2008 | 169 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2009 | 376 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 1146 | 0.020 |
Why?
|
| Sex Factors | 1 | 2008 | 979 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2005 | 49 | 0.020 |
Why?
|
| Physical Fitness | 1 | 2005 | 91 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2007 | 477 | 0.010 |
Why?
|
| Cardiac Catheterization | 1 | 1987 | 281 | 0.010 |
Why?
|
| Lactates | 1 | 2004 | 29 | 0.010 |
Why?
|
| Cardiotonic Agents | 1 | 2004 | 53 | 0.010 |
Why?
|
| Coronary Stenosis | 1 | 2004 | 39 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2003 | 70 | 0.010 |
Why?
|
| Lipoproteins, HDL | 1 | 2003 | 36 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2003 | 93 | 0.010 |
Why?
|
| Liver | 1 | 2007 | 851 | 0.010 |
Why?
|
| Surgical Wound Infection | 1 | 2004 | 115 | 0.010 |
Why?
|
| Probability | 1 | 2003 | 170 | 0.010 |
Why?
|
| Epinephrine | 1 | 2002 | 44 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 298 | 0.010 |
Why?
|
| Menstrual Cycle | 1 | 2002 | 82 | 0.010 |
Why?
|
| Norepinephrine | 1 | 2002 | 102 | 0.010 |
Why?
|
| Recurrence | 1 | 2004 | 642 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 860 | 0.010 |
Why?
|
| Acyl-CoA Oxidase | 1 | 2000 | 7 | 0.010 |
Why?
|
| Urban Health | 1 | 2001 | 40 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2011 | 3033 | 0.010 |
Why?
|
| Coenzyme A Ligases | 1 | 2000 | 13 | 0.010 |
Why?
|
| Oxidoreductases | 1 | 2000 | 64 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2000 | 185 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2001 | 98 | 0.010 |
Why?
|
| Length of Stay | 1 | 2004 | 811 | 0.010 |
Why?
|
| Frail Elderly | 1 | 2001 | 109 | 0.010 |
Why?
|
| Mitochondrial Proteins | 1 | 2000 | 102 | 0.010 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2000 | 147 | 0.010 |
Why?
|
| Incidence | 1 | 2003 | 1375 | 0.010 |
Why?
|
| Transfection | 1 | 2000 | 692 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2001 | 291 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2011 | 6629 | 0.010 |
Why?
|
| Prognosis | 1 | 2003 | 1750 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2001 | 777 | 0.010 |
Why?
|
| Social Support | 1 | 2001 | 371 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 1543 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2003 | 1988 | 0.010 |
Why?
|
| Prevalence | 1 | 2001 | 1380 | 0.010 |
Why?
|
| Cell Line | 1 | 2000 | 2037 | 0.010 |
Why?
|
| Atrial Fibrillation | 1 | 2004 | 837 | 0.010 |
Why?
|
| Child | 1 | 2003 | 4522 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2000 | 1514 | 0.010 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 1990 | 45 | 0.000 |
Why?
|
| Thyrotropin | 1 | 1988 | 34 | 0.000 |
Why?
|
| Myocardial Infarction | 1 | 1990 | 914 | 0.000 |
Why?
|